Several health insurers have reportedly secured a victory in their fight against UK pharmaceutical giant AstraZeneca last week as the companies won the fight to keep the case at state-level court.
Reports say AstraZeneca and generic drug makers sought to move the case to federal court on the grounds that the pay-for-delay lawsuit involved the issue of whether the patent in question was valid at the time of any agreement made between the companies. Insurers including Blue Cross and Blue Shield as well as Aetna are accusing the pharmaceutical firms of illegally conspiring to delay the release of generic forms of medication.
But US District Judge Gerald McHugh ruled last week that while the question of the patent’s validity is relevant, it is not dispositive. “Plaintiffs can conceivably prove the existence of anticompetitive conduct in violation of state antitrust law without litigating the patent issue, but by instead relying on the nature of the settlements themselves,” he said.
Plaintiffs argue that AstraZeneca’s pay-for-delay agreements are considered anticompetitive under the precedence of the Supreme Court’s 2013 ruling in FTC v. Actavis.
Full content: Courthouse News Service
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Senators Urged to Expedite Gail Slater’s Confirmation as DOJ Antitrust Chief
Feb 11, 2025 by
CPI
Former Michigan Asphalt Executive Pleads Guilty in Bid-Rigging Scheme
Feb 11, 2025 by
CPI
Ballard Spahr Expands Litigation Team with Addition of Antitrust Attorney in Seattle
Feb 11, 2025 by
CPI
Portuguese Court Overturns €225 Million Fine for Banking Collusion Due to Statute of Limitations
Feb 11, 2025 by
CPI
Binance and SEC Request Stay in Crypto Lawsuit Amid New Regulatory Task Force
Feb 11, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon